Immunobiology of transplantation: Impact on targets for large and small molecules

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 2, 2011, Pages 229-242

  Azimzadeh, A M ^a   Lees, J R ^a   Ding, Y ^a   Bromberg, J S ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; ALEMTUZUMAB; AZATHIOPRINE; BELATACEPT; BELIMUMAB; CD11B ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; COMPLEMENT; CYCLOSPORIN A; DEXAMETHASONE; EFALIZUMAB; EVEROLIMUS; FC RECEPTOR; FINGOLIMOD; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 2 RECEPTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; TASOCITINIB; THYMOCYTE ANTIBODY; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ALLOGRAFT; ALLOIMMUNITY; ARTICLE; B LYMPHOCYTE; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CLINICAL TRIAL; DENDRITIC CELL; DRUG EFFECT; DRUG TARGETING; ENDOTHELIUM CELL; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; IMMUNOBIOLOGY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; MESENCHYMAL STEM CELL; NATURAL KILLER CELL; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PSORIASIS;

ADAPTIVE IMMUNITY; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNITY, INNATE; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION;

EID: 79960598337     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.106     Document Type: Article

References (71)

1. Bluestone, J.A., Auchincloss, H., Nepom, G.T., Rotrosen, D., St Clair, E.W. & Turka, L.A. The Immune Tolerance Network at 10 years: tolerance research at the bedside. Nat. Rev. Immunol. 10, 797-803 (2010).
2. Nankivell, B.J. & Alexander, S.I. Rejection of the kidney allograft. N. Engl. J. Med. 363, 1451-1462 (2010).
3. Mucida, D. & Cheroutre, H. The many face-lifts of CD4 T helper cells. Adv. Immunol. 107, 139-152 (2010).
4. Kirk, A.D., Turgeon, N.A. & Iwakoshi, N.N. B cells and transplantation tolerance. Nat. Rev. Nephrol. 6, 584-593 (2010).
5. Powell, J.D. & Delgoffe, G.M. The mammalian target of rapamycin: linking T?cell differentiation, function, and metabolism. Immunity 33, 301-311 (2010).
6. Weir, M.R. et al. mTOR inhibition: the learning curve in kidney transplantation. Transpl. Int. 23, 447-460 (2010).
7. Flechner, S.M., Kobashigawa, J. & Klintmalm, G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin. Transplant. 22, 1-15 (2008). (Pubitemid 351149996)
8. Busque, S. et al. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am. J. Transplant. 9, 1936-1945 (2009).
9. Kirchner, V.A. et al. Anti-CD25 antibody (daclizumab) maintenance therapy in pancreas transplantation. Transplant. Proc. 42, 2003-2005 (2010).
10. Habicht, A. et al. Novel insights into the mechanism of action of FTY720 in a transgenic model of allograft rejection: implications for therapy of chronic rejection. J. Immunol. 176, 36-42 (2006). (Pubitemid 43023246)
11. Posselt, A.M. et al. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am. J. Transplant. 10, 1870-1880 (2010).
12. Major, E.O. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu. Rev. Med. 61, 35-47 (2010).
13. Wood, K.J., Bushell, A.R. & Jones, N.D. The discovery of immunological tolerance: now more than just a laboratory solution. J. Immunol. 184, 3-4 (2010).
14. Kawai, T. & Benedict Cosimi, A. Induction of tolerance in clinical kidney transplantation. Clin. Transplant. 24 (suppl. 22), 2-5 (2010).
15. Paterson, A.M., Vanguri, V.K. & Sharpe, A.H. SnapShot: B7/CD28 costimulation. Cell 137, 974-974.e1 (2009).
16. Bluestone, J.A., St Clair, E.W. & Turka, L.A. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 24, 233-238 (2006).
17. Larsen, C.P. et al. Pillars article: long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996. 381: 434-438. 1996. (Pubitemid 26162734)
18. J. Immunol. 186, 2693-2697 (2011).
19. Vincenti, F. et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am. J. Transplant. 10, 535-546 (2010).
20. Elgueta, R., Benson, M.J., de Vries, V.C., Wasiuk, A., Guo, Y. & Noelle, R.J. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 229, 152-172 (2009).
21. Ford, M.L. & Larsen, C.P. Translating costimulation blockade to the clinic: lessons learned from three pathways. Immunol. Rev. 229, 294-306 (2009).
22. Law, C.L. & Grewal, I.S. Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges. Adv. Exp. Med. Biol. 647, 8-36 (2009).
23. Croft, M. The role of TNF superfamily members in T-cell function and diseases. Nat. Rev. Immunol. 9, 271-285 (2009).
24. del Rio, M.L., Buhler, L., Gibbons, C., Tian, J. & Rodriguez-Barbosa, J.I. PD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation. Transpl. Int. 21, 1015-1028 (2008).
25. Ansari, M.J. & Sayegh, M.H. Costimulation couture: a designer approach to regulating autoimmunity. J. Clin. Invest. 116, 2080-2083 (2006). (Pubitemid 44162314)
26. Bluestone, J.A., Thomson, A.W., Shevach, E.M. & Weiner, H.L. What does the future hold for cell-based tolerogenic therapy? Nat. Rev. Immunol. 7, 650-654 (2007). (Pubitemid 47123553)
27. Wieckiewicz, J., Goto, R. & Wood, K.J. T regulatory cells and the control of alloimmunity: from characterisation to clinical application. Curr. Opin. Immunol. 22, 662-668 (2010).
28. Lal, G. et al. Distinct inflammatory signals have physiologically divergent effects on epigenetic regulation of Foxp3 expression and Treg function. Am. J. Transplant. 11, 203-214 (2011).
29. Thomson, A.W. Tolerogenic dendritic cells: all present and correct? Am. J. Transplant. 10, 214-219 (2010).
30. Ford, M.L. & Larsen, C.P. Overcoming the memory barrier in tolerance induction: molecular mimicry and functional heterogeneity among pathogenspecific T-cell populations. Curr. Opin. Organ Transplant. 15, 405-410 (2010).
31. Awasthi, A., Murugaiyan, G. & Kuchroo, V.K. Interplay between effector Th17 and regulatory T cells. J. Clin. Immunol. 28, 660-670 (2008).
32. Halloran, P.F. et al. An integrated view of molecular changes, histopathology and outcomes in kidney transplants. Am. J. Transplant. 10, 2223-2230 (2010).
33. Turka, L.A., Wood, K. & Bluestone, J.A. Bringing transplantation tolerance into the clinic: lessons from the ITN and RISET for the Establishment of Tolerance consortia. Curr. Opin. Organ Transplant. 15, 441-448 (2010).
34. Thornley, T.B. et al. TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts. J. Immunol. 176, 1561-1570 (2006). (Pubitemid 43134300)
35. Miller, D.M. et al. TLR agonists abrogate co-stimulation blockade-induced mixed chimerism and transplantation tolerance. Ann. NY Acad. Sci. 1150, 149-151 (2008).
36. Zhang, X. et al. Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood 110, 228-236 (2007). (Pubitemid 47026839)
37. Asgari, E., Zhou, W. & Sacks, S. Complement in organ transplantation. Curr. Opin. Organ Transplant. 15, 486-491 (2010).
38. Morrell, C.N., Sun, H., Swaim, A.M. & Baldwin, W.M. 3rd. Platelets an inflammatory force in transplantation. Am. J. Transplant. 7, 2447-2454 (2007). (Pubitemid 47561602)
39. Swaim, A.F., Field, D.J., Fox-Talbot, K., Baldwin, W.M. 3rd & Morrell, C.N. Platelets contribute to allograft rejection through glutamate receptor signaling. J. Immunol. 185, 6999-7006 (2010).
40. Coquerelle, C. & Moser, M. DC subsets in positive and negative regulation of immunity. Immunol. Rev. 234, 317-334 (2010).
41. Suez-Alvarez, B., Lez-Vquez, A., Baltar, J.M., Ortega, F. & Lez-Larrea, C. Potential role of NKG2D and its ligands in organ transplantation: new target for immunointervention. Am. J. Transplant. 9, 251-257 (2009).
42. Kroemer, A. et al. The innate NK cells, allograft rejection, and a key role for IL-J. Immunol. 180, 7818-7826 (2008).
43. Kim, J. et al. The activating immunoreceptor NKG2D and its ligands are involved in allograft transplant rejection. J. Immunol. 179, 6416-6420 (2007).
44. Moretta, A., Marcenaro, E., Sivori, S., Della Chiesa, M., Vitale, M. & Moretta, L. Early liaisons between cells of the innate immune system in inflamed peripheral tissues. Trends Immunol. 26, 668-675 (2005). (Pubitemid 41628200)
45. Demirkiran, A., Hendrikx, T.K., Baan, C.C. & van der Laan, L.J. Impact of immunosuppressive drugs on CD4+CD25+FOXP3+ regulatory T cells: does in vitro evidence translate to the clinical setting? Transplantation 85, 783-789 (2008). (Pubitemid 351440740)
46. Zhang, N. et al. Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity 30, 458-469 (2009).
47. Garcia, M.R. et al. Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice. J. Clin. Invest. 120, 2486-2496 (2010).
48. Issa, F., Hester, J., Goto, R., Nadig, S.N., Goodacre, T.E. & Wood, K. Ex vivoexpanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model. Transplantation 90, 1321-1327 (2010).
49. Ochando, J.C. et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat. Immunol. 7, 652-662 (2006). (Pubitemid 43797347)
50. Shevach, E.M. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 25, 195-201 (2006). (Pubitemid 44224153)
51. Issa, F. & Wood, K.J. CD4+ regulatory T cells in solid organ transplantation. Curr. Opin. Organ Transplant. (2010); e-pub ahead of print 24 September 2010.
52. Collison, L.W. et al. IL-35-mediated induction of a potent regulatory T cell population. Nat. Immunol. 11, 1093-1101 (2010).
53. Guillonneau, C., Picarda, E. & Anegon, I. CD8+ regulatory T cells in solid organ transplantation. Curr. Opin. Organ Transplant. (2010); e-pub ahead of print 24 September 2010.
54. Cobbold, S.P., Adams, E., Nolan, K.F., Regateiro, F.S. & Waldmann, H. Connecting the mechanisms of T-cell regulation: dendritic cells as the missing link. Immunol. Rev. 236, 203-218 (2010).
55. Hauben, E. et al. Activation of the aryl hydrocarbon receptor promotes allograft-specific tolerance through direct and dendritic cell-mediated effects on regulatory T cells. Blood 112, 1214-1222 (2008).
56. Hill, M. & Cuturi, M.C. Negative vaccination by tolerogenic dendritic cells in organ transplantation. Curr. Opin. Organ Transplant. (2010); e-pub ahead of print 24 September 2010.
57. Boros, P., Ochando, J.C., Chen, S.H. & Bromberg, J.S. Myeloid-derived suppressor cells: natural regulators for transplant tolerance. Hum. Immunol. 71, 1061-1066 (2010).
58. Casiraghi, F., Noris, M. & Remuzzi, G. Immunomodulatory effects of mesenchymal stromal cells in solid organ transplantation. Curr. Opin. Organ Transplant. 15, 731-737 (2010).
59. Scandling, J.D. et al. Tolerance and chimerism after renal and hematopoieticcell transplantation. N. Engl. J. Med. 358, 362-368 (2008). (Pubitemid 351159235)
60. Kawai, T. et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N. Engl. J. Med. 358, 353-361 (2008). (Pubitemid 351159234)
61. Poirier, N., et al. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci. Transl. Med. 2, 17ra10 (2010).
62. Bour-Jordan, H. & Bluestone, J.A. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol. Rev. 229, 41-66 (2009).
63. Tedesco-Silva, H. et al.; FTY720 Study Group. Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation 82, 1689-1697 (2006). (Pubitemid 46035653)
64. Kelishadi, S.S. et al. Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys. J. Clin. Invest. 120, 1275-1284 (2010).
65. Vo, A.A. et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med. 359, 242-251 (2008). (Pubitemid 352008439)
66. Stegall, M.D. & Gloor, J.M. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr. Opin. Organ Transplant. 15, 8-10 (2010).
67. Chen, G. et al. Anti-CD45RB monoclonal antibody prolongs renal allograft survival in cynomolgus monkeys. Am. J. Transplant. 7, 27-37 (2007). (Pubitemid 44952853)
68. Schrer, C. et al. CCR5 blockade modulates inflammation and alloimmunity in primates. J. Immunol. 179, 2289-2299 (2007).
69. Shimizu, K. et al. Leukocyte integrin Mac-1 promotes acute cardiac allograft rejection. Circulation 117, 1997-2008 (2008). (Pubitemid 351543476)
70. Zhang, L., Moffatt-Bruce, S.D., Gaughan, A.A., Wang, J.J., Rajab, A. & Hadley, G .A. An anti-CD103 immunotoxin promotes long-term survival of pancreatic islet allografts. Am. J. Transplant. 9, 2012-2023 (2009).
71. Hahn, B.H. Targeted therapies in systemic lupus erythematosus: successes, failures and future. Ann. Rheum. Dis. 70 (suppl. 1), i64-i66 (2011).